nodes	percent_of_prediction	percent_of_DWPC	metapath
Tafluprost—PTGS2—skin cancer	0.881	1	CbGaD
Tafluprost—PTGFR—Prostanoid ligand receptors—PTGER4—skin cancer	0.00823	0.201	CbGpPWpGaD
Tafluprost—PTGFR—nipple—skin cancer	0.00618	0.143	CbGeAlD
Tafluprost—PTGS2—leg—skin cancer	0.00551	0.128	CbGeAlD
Tafluprost—PTGFR—Eicosanoid ligand-binding receptors—PTGER4—skin cancer	0.00547	0.133	CbGpPWpGaD
Tafluprost—PTGS2—hindlimb—skin cancer	0.00492	0.114	CbGeAlD
Tafluprost—Uveitis—Vemurafenib—skin cancer	0.00488	0.141	CcSEcCtD
Tafluprost—PTGFR—Small Ligand GPCRs—PTGER4—skin cancer	0.00453	0.11	CbGpPWpGaD
Tafluprost—PTGS2—appendage—skin cancer	0.00422	0.0979	CbGeAlD
Tafluprost—PTGS2—skin epidermis—skin cancer	0.00351	0.0815	CbGeAlD
Tafluprost—PTGFR—Prostaglandin Synthesis and Regulation—PTGER4—skin cancer	0.00314	0.0766	CbGpPWpGaD
Tafluprost—PTGFR—female reproductive system—skin cancer	0.00309	0.0717	CbGeAlD
Tafluprost—Common cold—Fluorouracil—skin cancer	0.00307	0.0889	CcSEcCtD
Tafluprost—Eyelid oedema—Imiquimod—skin cancer	0.00288	0.0832	CcSEcCtD
Tafluprost—PTGFR—head—skin cancer	0.00258	0.0599	CbGeAlD
Tafluprost—PTGS2—endothelium—skin cancer	0.00255	0.0591	CbGeAlD
Tafluprost—PTGS2—blood vessel—skin cancer	0.00235	0.0545	CbGeAlD
Tafluprost—PTGFR—lymph node—skin cancer	0.00181	0.042	CbGeAlD
Tafluprost—Visual acuity reduced—Temozolomide—skin cancer	0.00146	0.0423	CcSEcCtD
Tafluprost—PTGFR—GPCRs, Other—SMO—skin cancer	0.00133	0.0324	CbGpPWpGaD
Tafluprost—PTGS2—connective tissue—skin cancer	0.0012	0.028	CbGeAlD
Tafluprost—PTGFR—Prostaglandin Synthesis and Regulation—PTGS2—skin cancer	0.00119	0.0289	CbGpPWpGaD
Tafluprost—PTGS2—epithelium—skin cancer	0.00114	0.0265	CbGeAlD
Tafluprost—PTGS2—Signaling mediated by p38-alpha and p38-beta—MITF—skin cancer	0.00109	0.0267	CbGpPWpGaD
Tafluprost—PTGS2—skin of body—skin cancer	0.00109	0.0252	CbGeAlD
Tafluprost—PTGS2—Prostaglandin Synthesis and Regulation—PTGER4—skin cancer	0.00102	0.025	CbGpPWpGaD
Tafluprost—Nervous system disorder—Vismodegib—skin cancer	0.000965	0.0279	CcSEcCtD
Tafluprost—Eye irritation—Fluorouracil—skin cancer	0.000939	0.0272	CcSEcCtD
Tafluprost—PTGS2—lymphoid tissue—skin cancer	0.000881	0.0204	CbGeAlD
Tafluprost—Lacrimation increased—Fluorouracil—skin cancer	0.00087	0.0252	CcSEcCtD
Tafluprost—PTGFR—GPCRs, Class A Rhodopsin-like—MC1R—skin cancer	0.000854	0.0208	CbGpPWpGaD
Tafluprost—PTGS2—female reproductive system—skin cancer	0.000849	0.0197	CbGeAlD
Tafluprost—Dry eye—Temozolomide—skin cancer	0.000804	0.0233	CcSEcCtD
Tafluprost—Eye disorder—Vemurafenib—skin cancer	0.000799	0.0231	CcSEcCtD
Tafluprost—Urinary tract infection—Imiquimod—skin cancer	0.00079	0.0228	CcSEcCtD
Tafluprost—PTGFR—GPCR ligand binding—PTCH2—skin cancer	0.000771	0.0188	CbGpPWpGaD
Tafluprost—Photophobia—Fluorouracil—skin cancer	0.000753	0.0218	CcSEcCtD
Tafluprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—MC1R—skin cancer	0.000732	0.0178	CbGpPWpGaD
Tafluprost—Rhinitis—Imiquimod—skin cancer	0.000731	0.0212	CcSEcCtD
Tafluprost—PTGS2—head—skin cancer	0.00071	0.0165	CbGeAlD
Tafluprost—Eye pain—Temozolomide—skin cancer	0.0007	0.0202	CcSEcCtD
Tafluprost—Pruritus—Vismodegib—skin cancer	0.000696	0.0201	CcSEcCtD
Tafluprost—Eye disorder—Imiquimod—skin cancer	0.000682	0.0197	CcSEcCtD
Tafluprost—Eye irritation—Docetaxel—skin cancer	0.000678	0.0196	CcSEcCtD
Tafluprost—Cough—Vemurafenib—skin cancer	0.00065	0.0188	CcSEcCtD
Tafluprost—Lacrimation increased—Docetaxel—skin cancer	0.000628	0.0182	CcSEcCtD
Tafluprost—Nervous system disorder—Vemurafenib—skin cancer	0.000596	0.0172	CcSEcCtD
Tafluprost—PTGFR—GPCRs, Class A Rhodopsin-like—PTGER4—skin cancer	0.000562	0.0137	CbGpPWpGaD
Tafluprost—PTGFR—GPCR ligand binding—MC1R—skin cancer	0.000557	0.0136	CbGpPWpGaD
Tafluprost—Cough—Imiquimod—skin cancer	0.000554	0.016	CcSEcCtD
Tafluprost—PTGS2—Spinal Cord Injury—CSPG4—skin cancer	0.000546	0.0133	CbGpPWpGaD
Tafluprost—Nasopharyngitis—Fluorouracil—skin cancer	0.000521	0.0151	CcSEcCtD
Tafluprost—Nervous system disorder—Imiquimod—skin cancer	0.000508	0.0147	CcSEcCtD
Tafluprost—PTGS2—lymph node—skin cancer	0.000497	0.0115	CbGeAlD
Tafluprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—PTGER4—skin cancer	0.000481	0.0117	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—RHOU—skin cancer	0.000478	0.0117	CbGpPWpGaD
Tafluprost—Urinary tract infection—Temozolomide—skin cancer	0.000473	0.0137	CcSEcCtD
Tafluprost—Dyspnoea—Imiquimod—skin cancer	0.000462	0.0134	CcSEcCtD
Tafluprost—Urinary tract infection—Fluorouracil—skin cancer	0.000436	0.0126	CcSEcCtD
Tafluprost—Pruritus—Vemurafenib—skin cancer	0.00043	0.0124	CcSEcCtD
Tafluprost—Eye disorder—Temozolomide—skin cancer	0.000409	0.0118	CcSEcCtD
Tafluprost—Rhinitis—Fluorouracil—skin cancer	0.000404	0.0117	CcSEcCtD
Tafluprost—PTGFR—GPCR ligand binding—SHH—skin cancer	0.000397	0.00968	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—PTCH2—skin cancer	0.000395	0.00965	CbGpPWpGaD
Tafluprost—Cough—Bleomycin—skin cancer	0.000394	0.0114	CcSEcCtD
Tafluprost—Headache—Vemurafenib—skin cancer	0.000381	0.011	CcSEcCtD
Tafluprost—PTGFR—GPCR ligand binding—SMO—skin cancer	0.000376	0.00918	CbGpPWpGaD
Tafluprost—PTGFR—GPCR ligand binding—PTCH1—skin cancer	0.000376	0.00918	CbGpPWpGaD
Tafluprost—Nasopharyngitis—Docetaxel—skin cancer	0.000376	0.0109	CcSEcCtD
Tafluprost—Pruritus—Imiquimod—skin cancer	0.000367	0.0106	CcSEcCtD
Tafluprost—PTGFR—GPCR ligand binding—PTGER4—skin cancer	0.000366	0.00894	CbGpPWpGaD
Tafluprost—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CDK4—skin cancer	0.00036	0.00877	CbGpPWpGaD
Tafluprost—Vision blurred—Temozolomide—skin cancer	0.000359	0.0104	CcSEcCtD
Tafluprost—Cough—Temozolomide—skin cancer	0.000332	0.0096	CcSEcCtD
Tafluprost—Vision blurred—Fluorouracil—skin cancer	0.00033	0.00956	CcSEcCtD
Tafluprost—Dyspnoea—Bleomycin—skin cancer	0.000328	0.00949	CcSEcCtD
Tafluprost—Headache—Imiquimod—skin cancer	0.000325	0.00939	CcSEcCtD
Tafluprost—PTGFR—GPCR downstream signaling—MC1R—skin cancer	0.000315	0.00768	CbGpPWpGaD
Tafluprost—Nervous system disorder—Temozolomide—skin cancer	0.000305	0.00881	CcSEcCtD
Tafluprost—PTGS2—Overview of nanoparticle effects—IL6—skin cancer	0.000304	0.00741	CbGpPWpGaD
Tafluprost—Rhinitis—Docetaxel—skin cancer	0.000291	0.00843	CcSEcCtD
Tafluprost—PTGFR—Signaling by GPCR—MC1R—skin cancer	0.000286	0.00697	CbGpPWpGaD
Tafluprost—Nervous system disorder—Fluorouracil—skin cancer	0.000281	0.00812	CcSEcCtD
Tafluprost—Dyspnoea—Temozolomide—skin cancer	0.000277	0.00801	CcSEcCtD
Tafluprost—Eye disorder—Docetaxel—skin cancer	0.000272	0.00786	CcSEcCtD
Tafluprost—Pruritus—Bleomycin—skin cancer	0.000261	0.00753	CcSEcCtD
Tafluprost—Dyspnoea—Fluorouracil—skin cancer	0.000255	0.00738	CcSEcCtD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—SHH—skin cancer	0.000253	0.00616	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—SMO—skin cancer	0.000239	0.00584	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—PTCH2—skin cancer	0.000234	0.0057	CbGpPWpGaD
Tafluprost—Cough—Docetaxel—skin cancer	0.000221	0.00639	CcSEcCtD
Tafluprost—Pruritus—Temozolomide—skin cancer	0.00022	0.00635	CcSEcCtD
Tafluprost—PTGS2—Aryl Hydrocarbon Receptor—NRAS—skin cancer	0.000214	0.00521	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—PTGER4—skin cancer	0.000207	0.00505	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—SHH—skin cancer	0.000204	0.00497	CbGpPWpGaD
Tafluprost—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—skin cancer	0.000203	0.00496	CbGpPWpGaD
Tafluprost—Nervous system disorder—Docetaxel—skin cancer	0.000203	0.00586	CcSEcCtD
Tafluprost—Pruritus—Fluorouracil—skin cancer	0.000202	0.00586	CcSEcCtD
Tafluprost—Headache—Temozolomide—skin cancer	0.000195	0.00563	CcSEcCtD
Tafluprost—PTGFR—Signaling by GPCR—PTCH1—skin cancer	0.000193	0.00471	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—SMO—skin cancer	0.000193	0.00471	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	0.000192	0.00469	CbGpPWpGaD
Tafluprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—skin cancer	0.000191	0.00465	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—PTGER4—skin cancer	0.000188	0.00459	CbGpPWpGaD
Tafluprost—Dyspnoea—Docetaxel—skin cancer	0.000184	0.00533	CcSEcCtD
Tafluprost—PTGS2—Aryl Hydrocarbon Receptor—KRAS—skin cancer	0.000184	0.00449	CbGpPWpGaD
Tafluprost—PTGS2—C-MYB transcription factor network—CDKN2A—skin cancer	0.000181	0.00443	CbGpPWpGaD
Tafluprost—PTGS2—Spinal Cord Injury—CDK4—skin cancer	0.000181	0.00441	CbGpPWpGaD
Tafluprost—Headache—Fluorouracil—skin cancer	0.000179	0.00518	CcSEcCtD
Tafluprost—PTGFR—Signaling Pathways—GLI2—skin cancer	0.000177	0.00432	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—MC1R—skin cancer	0.000169	0.00412	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—GLI1—skin cancer	0.000166	0.00406	CbGpPWpGaD
Tafluprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—skin cancer	0.000164	0.004	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—SUFU—skin cancer	0.000158	0.00385	CbGpPWpGaD
Tafluprost—PTGS2—Aryl Hydrocarbon Receptor—HRAS—skin cancer	0.000156	0.00381	CbGpPWpGaD
Tafluprost—Pruritus—Docetaxel—skin cancer	0.000146	0.00423	CcSEcCtD
Tafluprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—skin cancer	0.00014	0.0034	CbGpPWpGaD
Tafluprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—skin cancer	0.000134	0.00326	CbGpPWpGaD
Tafluprost—PTGS2—C-MYB transcription factor network—NRAS—skin cancer	0.000132	0.00322	CbGpPWpGaD
Tafluprost—Headache—Docetaxel—skin cancer	0.000129	0.00374	CcSEcCtD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—CDK4—skin cancer	0.000123	0.003	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—SHH—skin cancer	0.00012	0.00294	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—RASA1—skin cancer	0.00012	0.00292	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—PTCH1—skin cancer	0.000114	0.00278	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—SMO—skin cancer	0.000114	0.00278	CbGpPWpGaD
Tafluprost—PTGS2—C-MYB transcription factor network—KRAS—skin cancer	0.000114	0.00277	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—PTGER4—skin cancer	0.000111	0.00271	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—FOXO4—skin cancer	9.81e-05	0.00239	CbGpPWpGaD
Tafluprost—PTGS2—C-MYB transcription factor network—HRAS—skin cancer	9.66e-05	0.00236	CbGpPWpGaD
Tafluprost—PTGS2—Selenium Micronutrient Network—IL6—skin cancer	8.91e-05	0.00217	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—PLIN2—skin cancer	8.57e-05	0.00209	CbGpPWpGaD
Tafluprost—PTGS2—Disease—CSPG4—skin cancer	8.25e-05	0.00201	CbGpPWpGaD
Tafluprost—PTGS2—Spinal Cord Injury—TP53—skin cancer	7.7e-05	0.00188	CbGpPWpGaD
Tafluprost—PTGS2—Spinal Cord Injury—IL6—skin cancer	7.04e-05	0.00172	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—CSPG4—skin cancer	6.91e-05	0.00169	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—TERT—skin cancer	6.55e-05	0.0016	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	5.89e-05	0.00144	CbGpPWpGaD
Tafluprost—PTGS2—Disease—ENO2—skin cancer	5.61e-05	0.00137	CbGpPWpGaD
Tafluprost—PTGS2—Disease—SHH—skin cancer	5.61e-05	0.00137	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—NRAS—skin cancer	5.52e-05	0.00135	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	5.24e-05	0.00128	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—BRAF—skin cancer	5.19e-05	0.00127	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—KRAS—skin cancer	4.75e-05	0.00116	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—ENO2—skin cancer	4.7e-05	0.00115	CbGpPWpGaD
Tafluprost—PTGS2—Disease—FOXO4—skin cancer	4.57e-05	0.00112	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—HRAS—skin cancer	4.04e-05	0.000985	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—IL6—skin cancer	3.87e-05	0.000943	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—NRAS—skin cancer	3.26e-05	0.000795	CbGpPWpGaD
Tafluprost—PTGS2—Disease—ERCC2—skin cancer	3.26e-05	0.000795	CbGpPWpGaD
Tafluprost—PTGS2—Disease—TERT—skin cancer	3.05e-05	0.000745	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—KRAS—skin cancer	2.81e-05	0.000685	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—ERCC2—skin cancer	2.73e-05	0.000665	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—TP53—skin cancer	2.49e-05	0.000608	CbGpPWpGaD
Tafluprost—PTGS2—Disease—BRAF—skin cancer	2.42e-05	0.00059	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—HRAS—skin cancer	2.39e-05	0.000582	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—IL6—skin cancer	2.28e-05	0.000557	CbGpPWpGaD
Tafluprost—PTGS2—Disease—NRAS—skin cancer	1.52e-05	0.000371	CbGpPWpGaD
Tafluprost—PTGS2—Disease—KRAS—skin cancer	1.31e-05	0.000319	CbGpPWpGaD
Tafluprost—PTGS2—Disease—HRAS—skin cancer	1.11e-05	0.000271	CbGpPWpGaD
Tafluprost—PTGS2—Disease—IL6—skin cancer	1.06e-05	0.00026	CbGpPWpGaD
